SAN DIEGO, CA--(Marketwired - January 19, 2016) - SpectraScience, Inc. (SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that it will be exhibiting its WavSTAT Optical Biopsy System at the Arab Health Conference at the Dubai International Convention and Exhibition Centre January 25-28. This is the largest conference of its kind in the Middle East and the second largest medical device conference in the world.
"This is a great opportunity for us to make inroads into a geographic location that is becoming one of the more important emerging markets for medical device companies. The level of interest in medical technology to improve patient outcomes and reduce overall cost has dramatically increased in recent years," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. He went on to say, "Our system provides clinical information in real time, while significantly reducing the number of unnecessary polypectomies and biopsies. And it does all that at a cost less than that of traditional biopsies by eliminating the need for pathology. The system is easy to use and does not require the clinician to have extensive additional training. It is designed to be so easy to use that even nurse endoscopists can adopt the system with only minimal training."
The WavSTAT Optical Biopsy System can be seen at Booth # Z5D19 in Zaabil Hall 5 at the Dubai International Convention and Exhibition Centre. Our representative, Graeme Smith, will be available to discuss potential business opportunities.
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
"This is a great opportunity for us to make inroads into a geographic location that is becoming one of the more important emerging markets for medical device companies. The level of interest in medical technology to improve patient outcomes and reduce overall cost has dramatically increased in recent years," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. He went on to say, "Our system provides clinical information in real time, while significantly reducing the number of unnecessary polypectomies and biopsies. And it does all that at a cost less than that of traditional biopsies by eliminating the need for pathology. The system is easy to use and does not require the clinician to have extensive additional training. It is designed to be so easy to use that even nurse endoscopists can adopt the system with only minimal training."
The WavSTAT Optical Biopsy System can be seen at Booth # Z5D19 in Zaabil Hall 5 at the Dubai International Convention and Exhibition Centre. Our representative, Graeme Smith, will be available to discuss potential business opportunities.
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
